The Institute of Neurology and Neurosurgery (INN) at Saint Barnabas prides itself in its involvement in the demanding world of neurological research over the last 20+ years. The INN conducts research associated with a variety of neurological disorders with a particular focus in adult and childhood epilepsies, as well as studies in autism spectrum disorder. Investigational drug and product studies are constantly being conducted to bring new and improved anti-epileptic drugs to the market. The following investigational drug trials are currently being conducted at INN. The study links are available at www.clinicaltrials.gov.
Open to Enrollment:
- Protocol LP352-302: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter
Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Dravet Syndrome. - Protocol LP352-301: A Phase 3 randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with Developmental and Epileptic Encephalopathies (DEE)
- Protocol: LP352-303 Longboard Pharmaceuticals, Inc. / “A Phase 3, Open-Label Study to Investigate the Long-Term Safety and Efficacy of LP352 in the Treatment of Seizures in Children and Adults with Developmental and Epileptic Encephalopathy”
- BHV7000-302: To determine safety and Efficacy of BHV7000 in Adults with Refractory Focal Onset Epilepsy.
- BHV7000-201: A Long term Open-Label study for those completed 12-week double-blind study.
- BHV7000-304: To Determine Safety, Efficacy and Tolerability of BHV7000 in patients with Idiopathic Generalized Epilepsy with Open-Label Extension study.
- EP0239 (RWE0944)
EP0239 Sleep Disturbances, Behavior, Activities of Daily Living, and Caregiver Burden Among Patients Diagnosed with Dravet Syndrome and Lennox-Gastaut Syndrome Initiating Treatment with Fenfluramine (Fintepla®): A Prospective Multicentre Study.
ClinicalTrials.gov Identifier: NCT04938427
- Protocol: TAK-935-3003: An Open-label study for Lennox-Gastaut syndrome(LGS)
Closed to Enrollment:
- HEP3: Human Epilepsy study for newly diagnosed, treatment responsive , or treatment resistant Idiopathic generalized Epilepsy in Adolescents and Adults (Institutional study in collaboration with NYU)
If you are interested in participating or learning more about our research please contact Munazza Malik, MD
Phone: 973-322-7425.